UK markets closed

Summit Therapeutics plc (SMMT)

NasdaqGM - NasdaqGM Delayed price. Currency in USD
Add to watchlist
8.69-2.23 (-20.47%)
At close: 04:00PM EDT
Show:
Income statement
Balance sheet
Annual

Cash flow

All numbers in thousands
Breakdown
ttm
31/12/2023
31/12/2022
31/12/2021
31/12/2020
Cash flows from operating activities
Net income
-116,025
-614,928
-78,782
-88,602
-52,697
Depreciation & amortisation
1,987
2,050
2,514
2,455
2,003
Stock-based compensation
20,840
14,108
11,948
12,804
1,766
Change in working capital
2,013
-2,368
8,616
-67
619
Accounts receivable
9
359
975
-1,138
212
Accounts payable
5,659
2,263
-4,132
-1,711
1,642
Other working capital
-93,842
-76,888
-42,206
-72,893
-48,532
Other non-cash items
-
527,168
3,038
497
-383
Net cash provided by operating activities
-93,763
-76,760
-41,582
-72,587
-48,111
Cash flows from investing activities
Investments in property, plant and equipment
-79
-128
-624
-306
-421
Purchases of investments
-244,009
-321,022
0
-
-
Sales/maturities of investments
321,022
208,165
0
-
-
Other investing activities
-
-475,015
-
-
-
Net cash used for investing activities
77,160
-587,774
-624
-306
-421
Cash flows from financing activities
Debt repayment
0
-24,686
-25,000
-110,000
0
Common stock issued
-
5,000
0
75,000
50,000
Other financing activities
-
-619
-155
-172
-48
Net cash used provided by (used for) financing activities
6,886
86,513
620,244
77,916
50,551
Net change in cash
-9,358
-577,182
576,816
5,374
2,575
Cash at beginning of period
70,969
648,607
71,791
66,417
63,842
Cash at end of period
61,252
71,425
648,607
71,791
66,417
Free cash flow
Operating cash flow
-93,763
-76,760
-41,582
-72,587
-48,111
Capital expenditure
-79
-128
-624
-306
-421
Free cash flow
-93,842
-76,888
-42,206
-72,893
-48,532